RecruitingNCT05559853

Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment

Development of a Clinical CEST MR Fingerprinting Method for Treatment Response Assessment in Brain Metastases


Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

119 participants

Start Date

Sep 22, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of this study is to develop and test a new magnetic resonance imaging (MRI) technique to see if it can be used to tell the difference between tumor growth from worsening of cancer and growth from the effects of treatment in participants who have brain tumors treated with radiation therapy called stereotactic radiosurgery (SRS).


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is developing a new MRI technique that may better show how brain tumors (and brain metastases) are responding to treatment, potentially providing earlier and more accurate information than standard MRI scans. **You may be eligible if (healthy volunteers):** - You are 18 or older - You do not have a known cancer diagnosis **You may also be eligible if (cancer patients):** - You are 18 or older - You have at least one untreated brain metastasis larger than 1 cm - Some participants need to be scheduled for stereotactic radiosurgery (SRS) for the brain metastasis **You may NOT be eligible if:** - You are pregnant or breastfeeding - You have a pre-existing condition that increases the risk of seizures, claustrophobia, or heart problems during the scan - You are under 18 Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTCEST-MRF

CEST-MRF enables accurate quantification of both proton exchange rates and volume fractions in a fraction of the time required by conventional pulse sequences will be developed and optimized.


Locations(1)

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05559853


Related Trials